Section Arrow
Quote
KPRX.NASDAQ
- Kiora Pharmaceuticals Inc.
Quotes are at least 15-min delayed:2026/04/14 19:25 EDT
After Hours
Last
 2.37
-0.07 (-2.87%)
Bid
2.4
Ask
2.49
High 2.44 
Low 2.37 
Volume 7 
Regular Hours (Closed)
Last
 2.44
0 (0.00%)
Day High 
2.53 
Prev. Close
2.44 
1-M High
2.91 
Volume 
116.12K 
Bid
2.4
Ask
2.49
Day Low
2.36 
Open
2.49 
1-M Low
1.77 
Market Cap 
9.64M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.21 
20-SMA 2.13 
50-SMA 2.12 
52-W High 4.18 
52-W Low 1.7645 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.64/-1.13
Enterprise Value
9.84M
Balance Sheet
Book Value Per Share
4.08
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HOTHHoth Therapeutics0.6459+0.134+26.18%-- 
After Hours 0.65 +0.0041 +0.63%
ALLOAllogene Therapeutics2.28-0.78-25.49%-- 
After Hours 2.19 -0.09 -3.95%
VRAXVirax Biolabs Group Limited0.148-0.0184-11.06%-- 
After Hours 0.1384 -0.0096 -6.49%
CMNDClearmind Medicine Inc.0.91-0.52-36.36%-- 
After Hours 0.8558 -0.0542 -5.96%
REPLReplimune Group1.95+0.25+14.71%-- 
After Hours 1.9001 -0.0499 -2.56%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.